Am80 (tamibarotene) and ATRA induce highly similar molecular responses and myeloid differentiation in non-APL AML, enhanced by LSD1/GCN5 inhibition and increased RARA expression.
A retinoid drug works like standard therapy in AML and combines well with epigenetic inhibitors, supporting ongoing clinical trials in this indication.
Tamibarotene (Am80) and ATRA induce nearly identical myeloid differentiation programs in non-APL AML cells via RARA; combination with LSD1/GCN5 epigenetic inhibitors significantly enhanced differentiation, providing mechanistic rationale for tamibarotene-based differentiation therapy in non-APL AML currently in early clinical trials.
What the study was
- Study design
- translational
- Category
- hematologic_malignancies
- Maturity
- preclinical
- Journal
- BMC Cancer
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.